Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.48 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | FLT4 | P35916 | 2/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | CIT | O14578 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.46 |
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
| ▸ | STK10 | O94804 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6266570 | 0.96 | EGFR (0.46) | EGFREHMT2EHMT1KDRSRC | |
| SCHEMBL6268116 | 0.92 | EHMT2 (0.57) | EHMT2EHMT1TLR9TLR7 | |
| SCHEMBL5618725 | 0.87 | EHMT2 (0.51) | EGFREHMT2EHMT1KDREPHB4 | |
| SCHEMBL8438071 | 0.82 | KDR (0.38) | EGFREHMT2EHMT1KDRMET | |
| SCHEMBL6269488 | 0.81 | EGFR (0.42) | EGFREHMT2EHMT1AXLRET | |
| SCHEMBL8436900 | 0.81 | EPHA2 (0.42) | EHMT2EHMT1KDRMETCHEK2 | |
| SCHEMBL5084456 | 0.81 | EGFR (0.67) | EGFRKDRSRCFLT4AXL | |
| SCHEMBL6266311 | 0.80 | EGFR (0.44) | EGFREHMT2EHMT1KDRERBB2 | |
| SCHEMBL8444662 | 0.80 | EPHA2 (0.44) | EHMT2EHMT1KDRCHEK2EPHB4 | |
| SCHEMBL27607881 | 0.79 | KDM4E (0.58) | EGFREHMT2EHMT1KDRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076612-A | Sulfur-containing heteroaromatic tricyclic KRAS inhibitors | 医睿世康药业研发公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117940452-A | Methods and compositions for treating cancer | 基因泰克公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-111936857-B | Reagents and methods for predicting response to therapy | 艾比克斯治疗私人有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117715936-A | Methods and compositions for treating cancer | 豪夫迈·罗氏有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-112805267-B | Carboxamide and sulfonamide derivatives as TEAD modulators | 豪夫迈·罗氏有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117545857-A | Methods and compositions for the treatment and diagnosis of cancer | 基因泰克公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117440826-A | Administration of treatment with anti-CD 20/anti-CD 3 bispecific antibodies | 基因泰克公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-114867494-B9 | anti-LY 6G6D antibodies and methods of use | 基因泰克公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-111213059-B | Diagnostic and therapeutic methods for cancer | 豪夫迈·罗氏有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-117321078-A | Administration for combination therapy with anti-CD 20/anti-CD 3 bispecific antibody and anti-CD 79B antibody drug conjugates | 豪夫迈·罗氏有限公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2016036873-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| WO-2013007765-A1 | FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| EP-2242493-A1 | DERIVATIVES OF GEFITINIB | Concert Pharmaceuticals Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009094216-A1 | DERIVATIVES OF GEFITINIB | CONCERT PHARMACEUTICALS INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2005065074-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-07-21 | — | — | WO | disclosed |
| EP-1546119-A1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| EP-1480650-A1 | NOVEL CRYSTALLINE FORMS OF THE ANTI-CANCER COMPOUND ZD1839 | AstraZeneca AB (SE) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004024703-A1 | PROCESS FOR THE PREPARATION OF 4- (3’-CHLORO-4’-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2003072108-A1 | NOVEL CRYSTALLINE FORMS OF THE ANTI-CANCER COMPOUND ZD1839 | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | WO | disclosed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |